Show what your company has to
offer
Showcase you company’s product or service and network with industry
professionals at the 4th
Pharmacovigilance Conference in India.
The two-day conference, to be held in Bangalore from March 8-9, brings
together pharmacovigilance, clinical research, medical information, and
regulatory professionals and academia to discuss the latest global challenges in
drug safety.
Your company can exhibit with a tabletop display and receive one
complimentary full-meeting registration and one exhibit personnel
registration.
Or become a Platinum Level Supporter and receive three complimentary
full-meeting registrations, three exhibit personnel registrations, and exclusive
branding and promotion opportunities.
Click
here for further details and apply
today.
|
|
Other
events of Interest
Download
the India Calendar of Events
|
|
Conference Highlights
- Updates on recently released GPvP Modules by EMA
- Japanese model of EPPV – a way forward for other Asian countries
- Challenges in authoring PSUR for generic manufacturers
- An insight into Drug Induced Liver Injury (DILI)
- Global regulatory compliance: challenges and the way forward
- Safety regulations in emerging Middle East region
- Efficient management of literature searching
- Enhanced productivity and quality through process re-engineering; case
studies
- Global outsourcing trends in PV – Indian potential and challenges by China,
Taiwan, and Latin America
- RSI management – best practices to safeguard against pitfalls
- Attrition and manpower stability; KPO perspective
- Technology-watch against safety hazard of spurious and adulterated drugs
- Training; A Formality or a Reality – an industry insight
- Panel discussion: compensation for trial related injuries
This Pharmacovigilance Conference is perfect for professionals with
experience in clinical safety and who are involved in:
- Pharmacovigilance
- Clinical research
- Risk management
- Compliance
- Medical information
- Regulatory affairs
- Academia
- Pharmacology
Thank You to our Media
Partner
|
|
|
|
|
No comments:
Post a Comment